1 / 17

World AIDS Conference 2014

World AIDS Conference 2014 Impact of short-term change in body mass index after antiretroviral therapy initiation on subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study

mahsa
Download Presentation

World AIDS Conference 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. World AIDS Conference 2014 Impact of short-term change in body mass index after antiretroviral therapy initiation on subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study A.C. Achhra, A. Mocroft, P. Reiss, C. Sabin, L. Ryom, S. de Wit, C. Smith, A. d'Arminio Monforte, A. Phillips, R. Weber, J. Lundgren, M.G. Law, The D:A:D Study Group

  2. Background 1917 U Alabama cohort • Excess weight is a growing concern in HIV-positive individuals on ART • ART initiation is often associated with weight gain • Thought to be a good prognostic indicator • Impact on cardiovascular health? • VA cohort: per 5lb. gain on ART initiation ~10% more risk of incident diabetes • Better understanding this relationship could help manage risk of serious events in HIV-positive individuals Tate 2012; Hasse 2014; Herrin (CROI 2013)

  3. Objective • To assess the relationship between short-term change in BMI after first ART initiation and the subsequent risk of: • cardiovascular disease (CVD) • diabetes mellitus (DM)

  4. Analysis time Methods (1) • Inclusion criteria and analysis time: • Exposure of interest: Absolute change in BMI (kg/m2) at 1 year post ART initiation

  5. Methods (2): Endpoints CVD • Cardiovascular disease (CVD): composite of myocardial infarction (MI), sudden cardiac death, or invasive procedure (coronary artery bypass graft, carotid endarterectomy, or angioplasty) or confirmed stroke • Validated in real time by a defined protocol DM • DM verified in a DAD event form or by the use of anti-diabetic drugs, more details at www.chip.dk

  6. Statistical Methods • BMI change as a continuous variable • Exploratory analysis of change in BMI • Incidence rate ratios (IRR) were determined using Poisson regression adjusted for relevant risk factors: • Adjusted for key risk factors identified in previous D:A:D analyses for each of the outcome; also CD4 and BMI at ART start and cohort • Models sequentially adjusted for key variables at different time points. • Assessed if pre-ART BMI (categorised) is an effect modifier for each of the outcomes • Provide category specific IRRs ( per unit change in BMI) Friis-Møller 2010; Petoumenos 2012

  7. BMI change post ART initiation Overall mean change at 1 year: 0.67

  8. Patient characteristics at ART initiation

  9. CVD • Overall, 97 CVD events in 43982 person-years= 2.21 events/1000 person-years (95% CI: 1.76-2.68) • 46 MIs, 33 strokes, 18 invasive procedures • The rates (/1000 person-years) (95% CI) by pre-ART BMI:

  10. Adjusted IRR for CVD per unit gain in BMI Over-weight 25-30 Obese >30 Underweight <18.5 Normal 18.5-25 Pre-ART BMI P for effect modification in adjusted models: 0.041.

  11. Adjusted for demographics All time-updated variables Adjusted IRR for CVD per unit gain in BMI Q3 23.0-25.5 Q4 >25 Q2 20.9-23.0 Pre-ART BMI Quartiles P for effect modification in adjusted models: 0.011

  12. Diabetes mellitus • Similar inclusion criteria • Those with DM before study entry excluded • 125 DM events in 9193 eligible individuals (43278 person-years), at the rate of 2.89/1000 person-years • The rates (/1000 person-years) by pre-ART BMI :

  13. Adjusted for demographics All time-updated variables Adjusted IRR for DM per unit gain in BMI Obese >30 Overweight 25-30 Normal 18.5-25 All patients* Underweight <18.5 Pre-ART BMI *P for effect modification in adjusted models:> 0.05.

  14. Sensitivity analyses • Results robust to following sensitivity analyses: • exclude IDU (resulted in smaller P value for CVD outcome) • restrict to those with viral load <400 copies/mL at 1 year • model % change in BMI

  15. Strengths and Limitations • Heterogeneous cohort with real-time outcome ascertainment • Many key potential confounders available • Modern cohort on contemporary regimens • Selected sample • BMI may not accurately reflect central obesity; waist-hip ratio unavailable • Life-style factors (e.g. diet/exercise) unavailable • Limited number of specific CVD events

  16. Conclusion • Short-term gain in BMI post ART initiation could be associated with the increased risk of CVD, largely in those with normal/mid-levels of pre-ART BMI • Need to be verified in different studies • Gain in BMI also associated with risk of diabetes in all groups • No appreciable change in risk of CVD with gain in BMI in those with high pre-ART BMI • Low power? Bias? Limitation of BMI? Regression to mean? • Interpret cautiously • Further research needed regarding weight management in this population

  17. Acknowledgements SteeringCommittee:Membersindicatedw/*;¢chair; CohortPIs:WEl-Sadr*(CPCRA),GCalvo*(BASS),FDabis*(Aquitaine),OKirk*(EuroSIDA),MLaw*(AHOD),Ad’ArminioMonforte*(ICONA),LMorfeldt*(HivBIVUS),CPradier*(Nice),PReiss*(ATHENA),RWeber*(SHCS),SDeWit*(Brussels) Cohortcoordinatorsanddatamanagers:MHillebreght,SZaheri,LGras,(ATHENA),MBruyand,SGeffard,(Aquitaine),HMcManus,SWright(AHOD),SMateu,FTorres(BASS),MDelforge(Brussels),GBartsch,GThompsen(CPCRA),JKjær(EuroSIDA),IuriFanti(ICONA),EFontas,CCaissotti(Nice),ASundström,GThulin(HivBIVUS),MRickenbach(SHCS) Statisticians:CASabin*,ANPhillips*,DAKamara,CJSmith,AMocroft D:A:Dcoordinatingoffice:LRyom,RBrandt,JTverland,DRaben,ABojesen,JNielsen,JDLundgren*¢ MemberoftheD:A:DOversightCommittee:BPowderly*,NShortman*,CMoecklinghoff*,GReilly*,XFranquet* D:A:Dworkinggroupexperts:Kidney:LRyom,AMocroft,OKirk*,PReiss*,MRoss,CAFux,PMorlat,OMoranne,AMKesselring,DAKamara,CJSmith,JDLundgren*¢MortalityCJSmith,LRyom,ANPhillips*,RWeber*,PMorlat,CPradier*,PReiss*,NFriis-Møller,JKowalska,JDLundgren*¢CancerCASabin*,LRyom,MLaw*,Ad'ArminioMonforte*,FDabis*,MBruyand,PReiss*,CJSmith,DAKamara,MBower,GFätkenheuer,ADonald,AGrulich,JDLundgren*¢ Externalendpointreviewer:ASjøl(CVD),PMeidahl(oncology),JSIversen(nephrology) Funding:‘OversightCommitteeforTheEvaluationofMetabolicComplicationsofHAART’withrepresentativesfromacademia,patientcommunity,FDA,EMAandaconsortiumofAbbVie,BoehringerIngelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F. Hoffmann-La Roche and Janssen Pharmaceuticals

More Related